Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million

Argenx, based in Breda, the Netherlands, and Halozyme Therapeutics, headquartered in Ghent, Belgium, signed a global collaboration and license deal that lets Argenx use Halozyme’s Enhanze drug delivery technology to develop multiple products.